Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

The clinical-stage biotechnology company said Tuesday that the study will enroll at least 60 participants who will receive either one EP-104GI dose, two doses or a placebo. After six months, eligible ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Young Noah has already been diagnosed with a heart condition, severe obstructive Laryngomalacia, scoliosis, malformation of ...

Announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial ...